JP2017505777A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505777A5 JP2017505777A5 JP2016549300A JP2016549300A JP2017505777A5 JP 2017505777 A5 JP2017505777 A5 JP 2017505777A5 JP 2016549300 A JP2016549300 A JP 2016549300A JP 2016549300 A JP2016549300 A JP 2016549300A JP 2017505777 A5 JP2017505777 A5 JP 2017505777A5
- Authority
- JP
- Japan
- Prior art keywords
- sdc
- trap
- daltons
- moiety
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012636 effector Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 2
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 1
- 229930195248 Macbecin Natural products 0.000 claims 1
- PLTGBUPHJAKFMA-UHFFFAOYSA-N Macbecin I Natural products N1C(=O)C(C)=CC=CC(C)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O PLTGBUPHJAKFMA-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- PLTGBUPHJAKFMA-BMJWZTMLSA-N [(2r,3s,5s,6r,7s,8e,10r,11s,12z,14e)-2,5,6-trimethoxy-3,7,9,11,15-pentamethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](C)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O PLTGBUPHJAKFMA-BMJWZTMLSA-N 0.000 claims 1
- 230000009056 active transport Effects 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical group N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 1
- 229960003648 ixazomib Drugs 0.000 claims 1
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 claims 1
- 229930192524 radicicol Natural products 0.000 claims 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 1
- 229950007866 tanespimycin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933224P | 2014-01-29 | 2014-01-29 | |
| US61/933,224 | 2014-01-29 | ||
| PCT/US2015/013440 WO2015116774A1 (en) | 2014-01-29 | 2015-01-29 | Targeted therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017505777A JP2017505777A (ja) | 2017-02-23 |
| JP2017505777A5 true JP2017505777A5 (enExample) | 2018-02-08 |
Family
ID=53757707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549300A Pending JP2017505777A (ja) | 2014-01-29 | 2015-01-29 | 標的化治療薬 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10117944B2 (enExample) |
| EP (1) | EP3099332A4 (enExample) |
| JP (1) | JP2017505777A (enExample) |
| WO (1) | WO2015116774A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| JP6576942B6 (ja) * | 2014-03-03 | 2019-11-27 | マドリガル ファーマシューティカルズ インコーポレイテッド | 標的治療薬 |
| PT109941B (pt) * | 2017-03-02 | 2021-02-09 | Hovione Farmaciência, S.A. | Conjugados de boro multifuncionais com uma estrutura tripodal, composições farmacêuticas e processos de preparação dos mesmos |
| EP4424683A3 (en) * | 2017-03-13 | 2024-11-06 | Lundbeck La Jolla Research Center, Inc. | Dual magl and faah inhibitors |
| AU2018386218A1 (en) * | 2017-12-14 | 2020-07-02 | Tva (Abc), Llc | HSP90-targeting conjugates and formulations thereof |
| MA53607B1 (fr) * | 2018-09-13 | 2025-05-30 | Celgene Corporation | (r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés |
| TWI705813B (zh) | 2019-05-24 | 2020-10-01 | 國立交通大學 | 含有ganetespib的粒子與含有該粒子的藥學組成物及其在抗癌治療上的用途 |
| KR102322956B1 (ko) * | 2020-01-07 | 2021-11-09 | 이화여자대학교 산학협력단 | 신규 보르테조밉 전구약물 및 이의 용도 |
| WO2022010539A1 (en) * | 2020-07-08 | 2022-01-13 | Octagon Therapeutics, Inc. | Cancer cell modulators |
| EP4301418A1 (en) | 2021-03-03 | 2024-01-10 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates comprising an anti-bcma antibody |
| WO2023173026A1 (en) | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
| WO2024211234A1 (en) | 2023-04-05 | 2024-10-10 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
| WO2024211235A1 (en) | 2023-04-05 | 2024-10-10 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
| WO2024211236A2 (en) | 2023-04-05 | 2024-10-10 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| WO1999061055A1 (en) | 1998-05-22 | 1999-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and therapies based thereon |
| US8617514B2 (en) | 1999-02-22 | 2013-12-31 | Georgetown University | Tumor-targeted nanodelivery systems to improve early MRI detection of cancer |
| AU769235B2 (en) | 1999-04-09 | 2004-01-22 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| KR20030065502A (ko) | 2000-11-02 | 2003-08-06 | 슬로안-케테링인스티튜트퍼캔서리서치 | 에이치에스피90 저해제를 이용한 세포독성 제제의 효능을향상시키는 방법 |
| US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| AU2002364566B2 (en) | 2001-12-12 | 2009-03-26 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating HSP90 binding activity |
| GB0211578D0 (en) | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
| US7769423B2 (en) | 2002-09-11 | 2010-08-03 | Duke University | MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting |
| WO2004054624A1 (en) | 2002-12-12 | 2004-07-01 | Conforma Therapeutics Corporation | Cytotoxins and diagnostic imaging agents comprising hsp90 ligands |
| JP2007530596A (ja) | 2004-03-26 | 2007-11-01 | バン アンデル リサーチ インスティチュート | ゲルダナマイシンおよび誘導体はガン浸潤を阻害し、新規な標的を同定する |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| WO2007053792A2 (en) | 2005-11-05 | 2007-05-10 | Amplyx Pharmaceuticals, Inc. | Improving the pharmacokinetics of protease inhibitors and other drugs |
| EP1968607B1 (en) | 2005-12-02 | 2014-01-15 | Nabil Habib Lab | Treatment of cancer and other diseases |
| GB0526615D0 (en) | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
| ES2645095T3 (es) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| US8277807B2 (en) | 2006-10-12 | 2012-10-02 | Astex Therapeutics Limited | Pharmaceutical combinations |
| CA2680161A1 (en) * | 2007-03-05 | 2008-09-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
| US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
| JP2010533180A (ja) * | 2007-07-09 | 2010-10-21 | グレン エス. クウォン, | 治療剤 |
| EP2200653A2 (en) | 2007-09-10 | 2010-06-30 | University of Massachusetts | Mitochondria-targeted anti-tumour agents |
| WO2010028389A1 (en) | 2008-09-08 | 2010-03-11 | The Methodist Hospital Research Institute | Image-guided energy deposition for targeted drug delivery |
| WO2011116181A1 (en) | 2010-03-17 | 2011-09-22 | Caris Life Sciences, Inc. | Theranostic and diagnostic methods using sparc and hsp90 |
| AU2009293140A1 (en) | 2008-09-17 | 2010-03-25 | Endocyte, Inc. | Folate receptor binding conjugates of antifolates |
| US20110217241A1 (en) | 2008-11-14 | 2011-09-08 | University Of Maryland, Baltimore | Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging |
| CA2769619C (en) | 2009-08-17 | 2019-04-30 | Roche Glycart Ag | Targeted immunoconjugates |
| US20110268722A1 (en) | 2010-04-22 | 2011-11-03 | Siegelin Markus D | Combination therapies with mitochondrial-targeted anti-tumor agents |
| US20120064107A1 (en) * | 2010-05-18 | 2012-03-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other disease |
| US20120213854A1 (en) * | 2010-09-30 | 2012-08-23 | Fetzer Oliver S | Methods of treating a subject and related particles, polymers and compositions |
| WO2012052843A1 (en) | 2010-10-22 | 2012-04-26 | Universite De Strasbourg | Pochoxime conjugates useful for the treatment of hsp90 related pathologies |
| WO2012096919A1 (en) * | 2011-01-11 | 2012-07-19 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors |
| WO2013071163A2 (en) * | 2011-11-11 | 2013-05-16 | Millennium Pharamaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| WO2013158710A2 (en) * | 2012-04-18 | 2013-10-24 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| WO2013173391A1 (en) | 2012-05-15 | 2013-11-21 | Concortis Biosystems, Corp | Drug-conjugates, conjugation methods, and uses thereof |
| JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
| CA2923829A1 (en) | 2013-09-10 | 2015-03-19 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| KR102087850B1 (ko) | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-고분자-약물 접합체 |
| CN106132431A (zh) | 2013-10-15 | 2016-11-16 | 索伦托治疗有限公司 | 具有靶向分子和两种不同药物的药物偶联物 |
| WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| EP3082957B1 (en) | 2013-12-20 | 2022-04-06 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors |
-
2015
- 2015-01-29 WO PCT/US2015/013440 patent/WO2015116774A1/en not_active Ceased
- 2015-01-29 EP EP15742953.1A patent/EP3099332A4/en not_active Withdrawn
- 2015-01-29 JP JP2016549300A patent/JP2017505777A/ja active Pending
-
2016
- 2016-07-28 US US15/222,145 patent/US10117944B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505777A5 (enExample) | ||
| JP2017507150A5 (enExample) | ||
| JP2015512953A5 (enExample) | ||
| WO2020056198A3 (en) | Substituted benzazepine compounds, conjugates, and uses thereof | |
| EP3949969A3 (en) | Benzazepine compounds, conjugates, and uses thereof | |
| JP2012144574A5 (enExample) | ||
| WO2015095301A3 (en) | Cytotoxic peptides and conjugates thereof | |
| WO2008083174A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| WO2009110940A3 (en) | Virus-, bacteria-, and fungi-interacting layered phyllosilicates and methods of use | |
| WO2015021358A3 (en) | Compounds and methods for inhibiting phosphate transport | |
| HK1222122A1 (zh) | 选择性药物递送组合物及使用方法 | |
| CL2007002593A1 (es) | Compuestos derivados de 4-heteroaril-piridina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como rechazo de organos transplantados, sindromes autoinmunes y cancer. | |
| EA201390642A1 (ru) | Цитотоксические агенты, содержащие новые производные анзамитоцина | |
| MX2010005385A (es) | Medicamentos topicos para la terapia antimicotica. | |
| MX2017013167A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
| WO2015134464A3 (en) | Targeted therapeutics | |
| CA2902372C (en) | Polymer conjugate for delivery of a bioactive agent | |
| EP2548552A3 (en) | Titration package for 1-amino-alkylcylohexanes | |
| GB0710121D0 (en) | Antifungal agents | |
| CL2008000254A1 (es) | Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer. | |
| JP2016539156A5 (enExample) | ||
| WO2011054837A3 (de) | Bifunktionale prodrugs und drugs | |
| WO2015042414A8 (en) | Multicyclic compounds and methods of using same | |
| JP2016515550A5 (enExample) | ||
| WO2012159027A3 (en) | Osw-1 analogs and conjugates, and uses thereof |